Bayer builds €35m centre in Germany to develop biologicals

13 December 2010 15:51  [Source: ICIS news]

LONDON (ICIS)--Bayer HealthCare has begun building a new €35m ($46m) centre at the group’s pharmaceutical and chemical park in Wuppertal, Germany, for the biotechnological production of pharmaceuticals, the German chemicals producer said on Monday.

The new facility, on an area of around 1,000sqm, would go into operation in late 2012, and help expand the development of Bayer’s biologicals, it added.

"For a research-oriented pharmaceutical and chemical company like Bayer, innovation is the key to future growth,” said Wolfgang Plischke, a member of the board of management at Bayer responsible for innovation, technology and environment.

“The new cell biology facility centre represents an investment in our long-term success,” Plischke added.

Biologicals are drugs that are manufactured by biotechnological methods. The main focus of Bayer HealthCare is on antibodies, coagulation factors and other therapeutic proteins, the company said.

"The new facility centre will enable us to increase our production capacities in order to manufacture enough material for the late phases in clinical development for an increased number of potential active ingredients," said Andreas Busch, a member of the executive committee at Bayer HealthCare.

($1 = €0.76)

To discuss issues facing the chemical industry visit ICIS connect

By: Franco Capaldo
+44 (0)20 8652 3214

AddThis Social Bookmark Button

For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.

Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.

Printer Friendly